HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells (Q38777310)

6 September 2017

title

HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells (English)

1 reference

6 September 2017

Zhihao Wang

1

1 reference

6 September 2017

Pengchao Hu

series ordinal

2

1 reference

6 September 2017

Fang Tang

series ordinal

3

1 reference

6 September 2017

Conghua Xie

series ordinal

4

1 reference

6 September 2017

language of work or name

1 reference

18 April 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

33

1 reference

6 September 2017

issue

5

1 reference

6 September 2017

page(s)

50

1 reference

Non-Small Cell Lung Cancer, Version 6.2015.

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Lung cancer in the era of precision medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Sorafenib in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

The BATTLE trial: personalizing therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Endocytosis of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Proteomic identification and functional characterization of MYH9, Hsc70, and DNAJA1 as novel substrates of HDAC6 deacetylase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Proteomics. Tissue-based map of the human proteome

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/27090797

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Sorafenib: from literature to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Drugging the HDAC6-HSP90 interplay in malignant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

HDAC6 inhibition restores ciliary expression and decreases tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Histone deacetylase 6 represents a novel drug target in the oncogenic Hedgehog signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Survival of cancer cells is maintained by EGFR independent of its kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

A kinase-independent role for EGF receptor in autophagy initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0765-5

HDAC6 activity is not required for basal autophagic flux in metastatic prostate cancer cells

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27090797

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27090797

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12032-016-0765-5

1 reference

Dimensions Publication ID

6 September 2017

1044649540

0 references

1 reference